IDH2 and central nervous system cancer: Conventional T1-contrast imaging has been initially applied to differentiate high-grade gliomas from low-grade ones according to the appearance of enhanced signals, while later studies focusing on the non-enhancing area that proposed a T2-FLAIR mismatch sign have been applied to predict IDH mutation (3, 4).